Aprea Therapeutics reported financial results for the second quarter ended June 30, 2026, revealing a net loss of $3.6 million, or $0.07 per basic share, on approximately 53.5 million weighted-average shares outstanding. The company held $41.2 million in cash and cash equivalents as of June 30, 2026, sufficient to fund operations into the first quarter of 2028. R&D expenses increased to $2.5 million from $1.9 million in the prior year period due to higher costs for the ACESOT-1051 trial. Clinically, enrollment in the Phase 1 dose escalation study for its WEE1 inhibitor APR-1051 is accelerating, with active sites expanding from three to ten and an expectation of reaching 6 to 10 patients per month by Q4 2026. Aprea Therapeutics operates as a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for biomarker-defined cancers.

On July 23, 2026, Aprea Therapeutics received notification from Nasdaq that it remains non-compliant with the $1.00 minimum bid price requirement. The company has been granted an additional 180-calendar day extension, until January 19, 2027, to regain compliance. To avoid delisting, the common stock's closing bid price must be at least $1.00 for 10 consecutive business days within this period. Aprea Therapeutics is a biopharmaceutical company that develops therapies for rare diseases.

At the 2026 annual meeting of stockholders, Aprea Therapeutics, Inc. stockholders approved an amendment to the certificate of incorporation to authorize the Board of Directors to effect a reverse stock split of common stock at a ratio between one-for-three and one-for-eight. Aprea Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for patients with respiratory diseases.